Opko Health, Inc.

304 articles with Opko Health, Inc.

• 

  Former Scripps and Humira Leader Richard Lerner Passes Away

  12/7/2021

  Richard Lerner, who played a significant role in shaping both Scripps Research and the San Diego life sciences ecosystem and developing AbbVie’s blockbuster drug Humira, died Dec. 2.

• OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/29/2021

  OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 30 through December 2, 2021.

• OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021

  10/25/2021

  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 28, 2021.

• GeneDx Announces the Sequencing of More Than 300,000 Clinical Patient Exomes

  9/21/2021

  GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, announced it has completed clinical genetic exome sequencing for more than 300,000 patients, making the company's dataset the largest of its kind in the world.

• OPKO Health to Participate in Two Upcoming Investment Conferences

  8/30/2021

  OPKO Health, Inc. announced that management will be participating in two upcoming virtual investor conferences.

• OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients

  8/30/2021

  OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE ® as a treatment for mild-to-moderate COVID-19.

• OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results

  7/29/2021

  OPKO Health, Inc. reports business highlights and financial results for the three months ended June 30, 2021.

• OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021

  7/20/2021

  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, July 29, 2021.

• OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference

  7/8/2021

  OPKO Health, Inc. announced that management will be participating in the Ladenburg Thalmann Healthcare Conference being held virtually July 13-14, 2021.

• OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx

  6/22/2021

  OPKO Health, Inc. announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO’s BioReference Laboratories.

• OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics

  6/21/2021

  OPKO Health, Inc. (NASDAQ: OPK) today announced that its subsidiary EirGen Pharma has entered into an agreement with Nicoya Macau Limited, an affiliate of Nicoya Therapeutics (Nicoya), for the development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan) of RAYALDEE ® for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD).

• OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland

  6/17/2021

  OPKO Health, Inc. announces that its subsidiary, EirGen Pharma, Ltd., has entered into a definitive agreement to sell one of its facilities in Waterford, Ireland to Horizon Therapeutics plc for $65 million in cash less certain assumed and accrued liabilities relating to transferred employees.

• OPKO Health to Participate in the Jefferies Virtual Healthcare Conference - May 27, 2021

  5/27/2021

  OPKO Health, Inc. announced that management will be participating in the Jefferies Virtual Healthcare Conference being held June 1-4, 2021.

• OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor

  5/24/2021

  OPKO Health, Inc. (NASDAQ: OPK) today announced a transfer of the licensed rights to RAYALDEE ® in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). On May 17, 2021, JT notified OPKO of its decision to terminate the exclusive agreement with OPKO’s subsidiary, EirGen Pharma, Ltd., for the development and commercialization of RAYALDEE ® in Japan based on a comprehensive review of its development pipeline.

• OPKO Health Reports 2021 First Quarter Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today

  4/28/2021

  OPKO Health, Inc. reports business highlights and financial results for the three months ended March 31, 2021.

• OPKO Health to Report First Quarter 2021 Financial Results on April 28, 2021

  4/22/2021

  OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Wednesday, April 28, 2021.

• OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today

  2/18/2021

  OPKO Health, Inc. reports business highlights and financial results for the three months ended December 31, 2020.

• OPKO Health to Report Fourth Quarter 2020 Financial Results on February 18, 2021

  2/3/2021

  OPKO Health, Inc. plans to report operating and financial results for the three months ended December 31, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, February 18, 2021.

• OPKO Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 39 th Annual J.P. Morgan Healthcare Conference being held virtually on January 11-14, 2021. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 13 th at 3:40 p.m. Eastern time. The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website and accessibl

• 

  Pfizer, OPKO One Step Closer to Approval of Pediatric Growth Hormone Deficiency Drug Somatrogon

  1/4/2021

  Pfizer and OPKO Health are one step closer to receiving approval for their jointly developed pediatric growth hormone deficiency drug, somatrogon, after the U.S. FDA recently accepted the companies’ regulatory submission for the therapy.